Xue Za Zhi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Xue za zhi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Xue Za Zhi Today - Breaking & Trending Today

China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),. ....

United States , Hong Kong , Western Australia , Innovent Biologics , Ascentage Pharma , Gujralt Olverembatinib , Eli Lilly , Prnewswire Ascentage Pharma , Dajun Yang , Adimab Incyte , Michael Yu , Xue Za Zhi , Major National , Md Anderson Cancer Center , American Society Of Hematology , National Major New Drug Discovery , China National Medical Products Administration , European Union , National Healthcare Security Administration , Dana Farber Cancer Institute , National Comprehensive Cancer Network , Drug Administration , National Reimbursement Drug List , European Medicines Agency , Manufacturing Program , Innovent Biologics Inc ,

InnoCare Announces Dosing of First Patient in Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP

/PRNewswire/ InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the first patient has been dosed in Phase II clinical. ....

Hong Kong , New Jersey , United States , Midi Pyrées , Jasmine Cui , Chunhua Lu , Prnewswire Innocare Pharma , Xue Za Zhi , Chinese Medical Association , China National Medical Products Administration , Chinese Society Of Hematology , Hemostasis Group , Drug Administration , Care Pharma , Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma , Mantle Cell Lymphoma , Marginal Zone Lymphoma , Central Nervous System Lymphoma , Breakthrough Therapy Designation , Multiple Sclerosis , Systemic Lupus Erythematosus , Primary Immune Thrombocytopenia , Chinese Society , Chinese Medical , Chinese Guideline ,

InnoCare Announces Dosing of First Patient in Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP

/PRNewswire/ InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that the first patient has been dosed in Phase II clinical. ....

Hong Kong , New Jersey , United States , Midi Pyrées , Jasmine Cui , Chunhua Lu , Prnewswire Innocare Pharma , Xue Za Zhi , Chinese Medical Association , China National Medical Products Administration , Chinese Society Of Hematology , Hemostasis Group , Drug Administration , Care Pharma , Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma , Mantle Cell Lymphoma , Marginal Zone Lymphoma , Central Nervous System Lymphoma , Breakthrough Therapy Designation , Multiple Sclerosis , Systemic Lupus Erythematosus , Primary Immune Thrombocytopenia , Chinese Society , Chinese Medical , Chinese Guideline ,

Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib, Marking a Clinical Breakthrough in the Treatment of Chronic Myeloid Leukemia

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),. ....

United States , Hong Kong , Qian Jiang , Western Australia , Innovent Biologics , Ascentage Pharma , Eli Lilly , Prnewswire Ascentage Pharma , Xiaojun Huang , Dajun Yang , Adimab Incyte , Yifan Zhai , Michael Yu , Healthquest Pharma , Xue Za Zhi , Major National , Guangzhou Healthquest Pharma Co Ltd Inc , Institute Of Hematology , Md Anderson Cancer Center , American Society Of Hematology , National Major New Drug Discovery , China National Medical Products Administration , European Union , Dana Farber Cancer Institute , Hematology Department At Peking University People Hospital , Incyte Corporation ,

Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib, Marking a Clinical Breakthrough in the Treatment of Chronic Myeloid Leukemia

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),. ....

United States , Hong Kong , Qian Jiang , Western Australia , Innovent Biologics , Ascentage Pharma , Eli Lilly , Prnewswire Ascentage Pharma , Xiaojun Huang , Dajun Yang , Adimab Incyte , Yifan Zhai , Michael Yu , Healthquest Pharma , Xue Za Zhi , Major National , Guangzhou Healthquest Pharma Co Ltd Inc , Institute Of Hematology , Md Anderson Cancer Center , American Society Of Hematology , National Major New Drug Discovery , China National Medical Products Administration , European Union , Dana Farber Cancer Institute , Hematology Department At Peking University People Hospital , Incyte Corporation ,